Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, B-Cell » Lymphoma, Large B-Cell, Diffuse
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, B-Cell » Lymphoma, Large B-Cell, Diffuse
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, B-Cell » Lymphoma, Large B-Cell, Diffuse
Description
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. MeSH
Hierarchy View
Subtype Terms (1)
Plasmablastic Lymphoma
21 drugs (17 approved, 4 experimental)
Phase 4 Indicated Drugs (17)
Phase 3 Indicated Drugs (72)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)
allogeneic adipose derived mesenchymal stem cell
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
autologous hematopoietic stem cells
autologous mononuclear stem cell
Phase 1 Indicated Drugs (101)
allogeneic gamma-delta t cells
anti-cd20 b9e9 scfv-streptavidin fusion protein
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes
autologous dendritic cells loaded with autologous tumor lysate
autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells
Other Experimental Indicated Drugs (15)
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (106)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Cancer and Leukemia Group B (CALGB)
Centre Hospitalier Schaffner France
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
China National Biotec Group Co., Ltd
Chinese Academy of Medical Sciences
Chinese Anti-Cancer Association
City of Hope National Medical Center
Eastern Cooperative Oncology Group
Fondazione Italiana Diabete Onlus
German Federal Ministry of Education and Research
Gruppo Italiano Terapie Innovative nei Linfomi
Innovent Biologics (Suzhou) Co. Ltd.
International Extranodal Lymphoma Study Group
Jiangsu Cancer Institute & Hospital
Laboratorio Elea S.A.C.I.F. y A.
Moorgreen Hospital, Southampton
Nanjing Yoko Biomedical Co., Ltd.
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
People's Liberation Army of China
Russian Academy of Medical Sciences
Organization Involved with Phase 2 Indications (275)
Academic and Community Cancer Research United
Apogee Biotechnology Corporation
Assistance Publique - Hôpitaux de Paris
Beijing InnoCare Pharma Tech Co., Ltd.
Blood and Marrow Transplant Clinical Trials Network
Case Western Reserve University
Center for International Blood and Marrow Transplant Research
Centro di Riferimento Oncologico - Aviano
Chongqing Precision Biotech Co., Ltd
Clinica Universidad de Navarra
ECOG-ACRIN Cancer Research Group
Foshan First People's Hospital
French Innovative Leukemia Organisation
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Groupe Hospitalier Public Sud Oise
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Henan University of Traditional Chinese Medicine
Hoosier Cancer Research Network
Hospital Dr. Jose Molina Orosa
Hospital Universitario Central de Asturias
Hospital Universitari Son Dureta
HOVON - Dutch Haemato-Oncology Association
Huizhou People's Central Hospital
Icahn School of Medicine at Mount Sinai
ImmunoVaccine Technologies, Inc.
Instytut Hematologii i Transfuzjologii, 02-776 Warszawa ul. Indiry Gandhi 14
La Jolla Pharmaceutical Company
Medical City Children's Hospital, Dallas
National Cancer Institute, France
National Cheng Kung University
National Institutes of Health (NIH)
Oregon Health and Science University
Ospedale S. Giovanni Bellinzona
Pavlov First Saint Petersburg State Medical University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Polish Lymphoma Research Group
Quebec Clinical Research Organization in Cancer
Royal Marsden Hospital NHS Trust
Shanghai Ming Ju Biotechnology Co., Ltd.
Shanghai YingLi Pharmaceutical Co. Ltd.
Shijiazhuang Pharma Group (CSPC)
Southampton University Hospital NHS Foundation Trust
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
Taichung Veterans General Hospital
Technical University of Munich
Territorial Hospital Group (GHT) Rance Emeraude
The Alvin and Lois Lapidus Cancer Institute
The Christie NHS Foundation Trust
The Foundation Institute San Raffaele G. Giglio of Cefalù
The Wayne D. Kuni and Joan E. Kuni Foundation
Universidad Autonoma de Madrid
Universidad Autonoma de Nuevo Leon
Universidad Complutense de Madrid
University of California, Los Angeles
University of California, San Diego
University of Colorado, Denver
University of Erlangen-Nuremberg
University of Las Palmas de Gran Canaria
University of Medicine and Dentistry of New Jersey
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Picardie Jules Verne
University of Roma La Sapienza
University of Southern California
University of Texas at Houston
University of Texas, San Antonio
Organization Involved with Phase 1 Indications (51)
Boryung Pharmaceutical Company
British Columbia Cancer Agency
California Institute for Biomedical Research
Cellular Biomedicine Group Ltd.
Malaghan Institute of Medical Research
Medical University of South Carolina
Nanjing Bioheng Biotech Co., Ltd.
Olivia Newton-John Cancer Research Institute
Shanghai Cell Therapy Engineering Research Institute
Organization Involved with Other Experimental Indications (11)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
